Antibodies

23 Oct 2018 UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
22 Oct 2018 Genmab Announces Positive Topline Results in Phase III CASSIOPEIA Study of Daratumumab in Front Line Multiple Myeloma
22 Oct 2018 Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Durable Four-Year Survival Benefits in Patients with Advanced Melanoma
22 Oct 2018 Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Durable Clinical Benefit in Previously Untreated Patients with MSI-H or dMMR Metastatic Colorectal Cancer
22 Oct 2018 Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
22 Oct 2018 Genentech’s Tecentriq Plus Chemotherapy (Carboplatin and Abraxane) as an Initial Treatment Helped People With Advanced Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone
22 Oct 2018 GSK presents new efficacy and safety data of an anti GM-CSF antibody in patients with rheumatoid arthritis
21 Oct 2018 FDA Approves Label Update for Genentech’s Rituxan (Rituximab) in Two Rare Forms of Vasculitis
21 Oct 2018 Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Shows Promising Results in Patients with Advanced Form of Bladder Cancer
21 Oct 2018 Merck’s KEYTRUDA® (pembrolizumab) Showed a Complete Response Rate of Nearly 40 Percent in Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Standard of Care
21 Oct 2018 First Presentation of Early Data for Merck’s Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 Congress
21 Oct 2018 Genentech’s Tecentriq in Combination With Abraxane Improves Outcomes as an Initial Treatment for People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
21 Oct 2018 Daiichi Sankyo Presents Updated Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Expressing Advanced Colorectal Cancer at 2018 European Society for Medical Oncology (ESMO) Congress
21 Oct 2018 Janssen Announces New Three-Year TREMFYA® (Guselkumab) Data Demonstrates Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis
21 Oct 2018 Mylan Launches Hulio™ (Biosimilar Adalimumab) in Markets Across Europe
21 Oct 2018 CHMP Recommends EU Marketing Authorisation of lanadelumab for the Prevention of HAE Attacks
21 Oct 2018 FDA approves asthma indication for Dupixent® (dupilumab)
21 Oct 2018 TESARO Announces Data Presentations at ESMO 2018 Congress
21 Oct 2018 OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer
21 Oct 2018 Innate Pharma announces phase II results from monalizumab and cetuximab combination in head and neck cancer at the ESMO 2018 congress
19 Oct 2018 Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility
19 Oct 2018 Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma
19 Oct 2018 Innovent Announces First Patient Dosed in a Phase I Clinical Trial of Anti-CTLA-4 Monoclonal Antibody
19 Oct 2018 UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis Into Confirmatory Development Phase
19 Oct 2018 Data on Glenmark Pharmaceuticals' GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody in Development for the Treatment of Moderate-to-Severe Atopic Dermatitis, to be Presented at the Fall Clinical Dermatology Conference

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top